ICARE-LCS QUERI Partnered Evaluation Initiative: Integrating Comprehensive Tobacco Treatment to Enhance Lung Cancer Screening

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorVA Office of Research and Development

About this trial

Lung cancer is the leading cause of cancer-related death among Veterans with 90% of cases attributable to smoking. Lung cancer screening (LCS) combined with smoking cessation saves the most lives. ICARE-LCS seeks to decrease health inequality and improve Veteran health by reducing smoking rates among Veterans receiving LCS. ICARE-LCS will use implementation methods to inform national cancer prevention efforts and build infrastructure necessary to support broad implementation of high-impact tobacco dependence treatment (TDT) processes in LCS programs.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

This is a VAMC based Quality Improvement Partnered Evaluation Initiative. VA sites from around the country that agreed to participate are included.

Disqualifiers

N/A

Trial population

Participating VA Medical Centers

Trial design

Design model

Other

Time perspective

Other

Treatments tested in this trial

  • External Facilitation

    Other intervention

    Multi-component facilitation strategy to address identified implementation needs

Treatment groups

7 Participants
are divided into 2 treatment groups
Group A: Veterans Participating in Lung Cancer Screening who Smoke0 interventions
Group B: Participating VA Medical Centers1 intervention

Trial outcomes

Primary outcomes

1

Receipt of Combined Tobacco Dependence Treatment

Participation in counseling and pharmacotherapy within 90 days of lung cancer screening referral

Time frame
Approximately 3 years

Secondary outcomes

1

Number of Veterans Receiving ANY Tobacco Dependence Treatment Therapy

Participation in ANY tobacco dependence treatment therapy (including but not limited to pharmacotherapy or counseling) for eligible Veterans in lung cancer screening who smoke

Time frame
Approximately 3 years
2

Number of Veterans Receiving of Pharmacotherapy or Counseling Alone

Participation in individual treatment options among patients in lung cancer screening who smoke. These are defined as Pharmacotherapy (nicotine replacement, bupropion, varenicline, combination treatments) and counseling (individual or group tobacco visits delivered by any modality).

Time frame
Approximately 3 years
3

Cost Associated with Tobacco Dependence Treatment Among Lung Cancer Screening Participants who Smoke

Evaluate facility level costs and economic impacts of tobacco treatment for patients in lung cancer screening who smoke.

Time frame
Approximately 3 years
4

Rate of Short-term Cessation Among Veterans In Lung Cancer Screening who Smoke

Short-term cessation data among eligible Veterans in lung cancer screening who smoke as gathered by chart review

Time frame
Approximately 3 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

VA Office of Research and Development

Lead sponsor

VA Oncology and Precision Medicine

Collaborator

VA Tobacco Use Treatment National Program Office

Collaborator

VA National Center for Lung Cancer Screening

Collaborator

This trial is not recruiting at the moment. You can still explore other options: